Findings from the randomized ATTENTION #ClinicalTrial demonstrate that #Aumolertinib plus #Apatinib significantly improves progression-free survival with manageable safety in treatment-naïve, #EGFR-mutant advanced #NSCLC.
#STTT #OpenAccess: doi.org/10.1038/s413...
A phase II #ClinicalTrial—evaluating #Aumolertinib + #Apatinib vs. aumolertinib monotherapy—revealed a manageable safety profile with improved progression-free survival in untreated, #EGFR-mutant, advanced #NSCLC patients.
#STTT #OpenAccess: doi.org/10.1038/s413...
Increase SEO Traffic with Free Backlinks from aéPiot
D J #GUGENHEIM
allgraph.ro/advanced-sea...
#AUMOLERTINIB
aepiot.com/advanced-sea...
cabildoabierto.ar/perfil/logo-ped.bsky.social
blueskystarterpack.com/starter-pack...
A phase II trial reveals neoadjuvant aumolertinib (3rd-gen EGFR-TKI) shows promising efficacy in unresectable stage III EGFR-mutant NSCLC! 🌟
@natcomms.nature.com @egfrpositiveuk.bsky.social
#Onco404 #Cancer #Kanser #LungCancer #AkciğerKanseri #NSCLC #MedSky #EGFR #Aumolertinib #ClinicalTrials
